{"filing":{"accession_number":"0001664710-26-000036","cik":"0001664710","ticker":"KROS","company_name":"Keros Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"kros-20260623.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000036/kros-20260623.htm"},"events":[{"id":13853,"run_id":12308,"accession_number":"0001664710-26-000036","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Keros Therapeutics appointed Anne Prener, M.D., Ph.D., as a director effective July 1, 2026. Dr. Prener brings significant clinical development and executive leadership experience to the Board. Her compensation package includes initial and annual equity grants totaling $300,000 in grant-date fair value plus a $41,500 annual cash retainer.","company_name":"Keros Therapeutics, Inc.","ticker":"KROS","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":11119,"accession_number":"0001664710-26-000036","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Anne Prener, M.D., Ph.D., as a director of Keros Therapeutics, effective July 1, 2026, based on a Board recommendation. While the disclosure includes details of her standard director compensation (initial and annual equity grants totaling $300,000 in grant-date fair value plus $41,500 annual cash retainer), the principal disclosed action is the appointment of a new director with significant clinical development and executive leadership experience, making this an exec_appointment event. The compensation details are ancillary to the appointment itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T20:04:40.712050+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11120,"accession_number":"0001664710-26-000036","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Anne Prener to Keros' Board of Directors, effective July 1, 2026. The press release emphasizes her clinical development expertise and executive leadership experience as valuable to the company's strategic advancement. Board appointments of experienced executives are material governance events affecting investor assessment of the company's leadership and direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T20:04:40.712050+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11119,"accession_number":"0001664710-26-000036","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Anne Prener, M.D., Ph.D., as a director of Keros Therapeutics, effective July 1, 2026, based on a Board recommendation. While the disclosure includes details of her standard director compensation (initial and annual equity grants totaling $300,000 in grant-date fair value plus $41,500 annual cash retainer), the principal disclosed action is the appointment of a new director with significant clinical development and executive leadership experience, making this an exec_appointment event. The compensation details are ancillary to the appointment itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T20:04:40.712050+00:00","company_name":"Keros Therapeutics, Inc.","ticker":"KROS","filing_date":"2026-06-25"},{"id":11120,"accession_number":"0001664710-26-000036","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Anne Prener to Keros' Board of Directors, effective July 1, 2026. The press release emphasizes her clinical development expertise and executive leadership experience as valuable to the company's strategic advancement. Board appointments of experienced executives are material governance events affecting investor assessment of the company's leadership and direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T20:04:40.712050+00:00","company_name":"Keros Therapeutics, Inc.","ticker":"KROS","filing_date":"2026-06-25"}]}